Repligen (RGEN) Gross Profit Margin: History & Chart

Repligen Corporation(RGEN)

Medical - Instruments & Supplies · Waltham, MA

$174.86-14.64 (-7.73%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Repligen Corporation

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

Waltham, MA

2,000 employees

www.repligen.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Olivier Loeillot

View full financials

RGEN Gross Margin Metrics

GROSS MARGIN

51.05%

GROSS MARGIN AVG TTM

50.84%

GROSS MARGIN AVG 3Y

49.80%

GROSS MARGIN AVG 5Y

52.67%

GROSS MARGIN AVG 10Y

53.84%

GROSS MARGIN AVG 15Y

55.14%

GROSS MARGIN AVG 20Y

60.02%

CURRENT VS TTM AVG

+0.41%

CURRENT VS 3Y AVG

+2.51%

CURRENT VS 5Y AVG

-3.08%

CURRENT VS 10Y AVG

-5.18%

CURRENT VS 15Y AVG

-7.41%

CURRENT VS 20Y AVG

-14.94%

SECTOR MEDIAN · HEALTHCARE

41.38%

median of 863 covered companies

CURRENT VS SECTOR MEDIAN

+23.37%

vs the sector median at left

NAME	MARKET CAP	GROSS MARGIN	TTM	3Y	5Y
Repligen Corporation (RGEN)	$9.87B	51.05%	50.84%	49.80%	52.67%
Bio-Rad Laboratories, Inc. (BIO)vs ›	$9.93B	51.90%	52.87%	53.77%	54.60%
The Ensign Group, Inc. (ENSG)vs ›	$10.03B	14.14%	15.74%	16.11%	16.54%
Henry Schein, Inc. (HSIC)vs ›	$9.66B	30.31%	29.43%	29.32%	29.12%
Krystal Biotech, Inc. (KRYS)vs ›	$9.63B	93.34%	92.85%	69.90%	46.60%
Vaxcyte, Inc. (PCVX)vs ›	$9.63B	0.00%	0.00%	0.00%	0.00%
Align Technology, Inc. (ALGN)vs ›	$10.13B	66.48%	69.16%	69.73%	70.75%
ImmunityBio, Inc. (IBRX)vs ›	$10.15B	94.63%	99.67%	99.84%	99.89%
Molina Healthcare, Inc. (MOH)vs ›	$10.19B	13.07%	12.36%	12.43%	12.55%
10x Genomics, Inc. (TXG)vs ›	$10.24B	70.03%	68.45%	69.94%	74.18%

NAME

MARKET CAP

GROSS MARGIN

TTM

Repligen Corporation (RGEN)

$9.87B

51.05%

50.84%

49.80%

52.67%

Bio-Rad Laboratories, Inc. (BIO)vs ›

$9.93B

51.90%

52.87%

53.77%

54.60%

The Ensign Group, Inc. (ENSG)vs ›

$10.03B

14.14%

15.74%

16.11%

16.54%

Henry Schein, Inc. (HSIC)vs ›

$9.66B

30.31%

29.43%

29.32%

29.12%

Krystal Biotech, Inc. (KRYS)vs ›

$9.63B

93.34%

92.85%

69.90%

46.60%

Vaxcyte, Inc. (PCVX)vs ›

$9.63B

0.00%

Align Technology, Inc. (ALGN)vs ›

$10.13B

66.48%

69.16%

69.73%

70.75%

ImmunityBio, Inc. (IBRX)vs ›

$10.15B

94.63%

99.67%

99.84%

99.89%

Molina Healthcare, Inc. (MOH)vs ›

$10.19B

13.07%

12.36%

12.43%

12.55%

10x Genomics, Inc. (TXG)vs ›

$10.24B

70.03%

68.45%

69.94%

74.18%

Gross Margin FAQ

What is the gross margin for Repligen Corporation (RGEN)?

The gross margin for RGEN stock is 51.05%.

Is Repligen Corporation's gross margin high or low?

The gross margin of 51.05% is in line with its 5-year average of 52.67%, near the high end of its 5-year range (23.18%–61.96%).

What is the TTM average gross margin for Repligen Corporation (RGEN)?

The TTM average gross margin for RGEN stock is 50.84%.

What is the 3Y average gross margin for Repligen Corporation (RGEN)?

The 3Y average gross margin for RGEN stock is 49.80%.

What is the 5Y average gross margin for Repligen Corporation (RGEN)?

The 5Y average gross margin for RGEN stock is 52.67%.

What is the 10Y average gross margin for Repligen Corporation (RGEN)?

The 10Y average gross margin for RGEN stock is 53.84%.

What is the 15Y average gross margin for Repligen Corporation (RGEN)?

The 15Y average gross margin for RGEN stock is 55.14%.

What is the 20Y average gross margin for Repligen Corporation (RGEN)?

The 20Y average gross margin for RGEN stock is 60.02%.

DATE	GROSS MARGIN
2026-06-30	53.08%
2026-03-31	50.70%
2025-12-31	47.21%
2025-09-30	53.24%
2025-06-30	49.98%
2025-03-31	53.65%
2024-12-31	23.18%
2024-09-30	50.03%
2024-06-30	46.17%
2024-03-31	50.13%
2023-12-31	43.41%
2023-09-30	25.89%
2023-06-30	50.17%
2023-03-31	50.51%
2022-12-31	51.44%
2022-09-30	56.90%
2022-06-30	58.46%
2022-03-31	60.10%
2021-12-31	56.01%
2021-09-30	57.64%
2021-06-30	61.96%
2021-03-31	58.17%
2020-12-31	51.70%
2020-09-30	57.87%
2020-06-30	57.85%
2020-03-31	57.97%
2019-12-31	51.25%
2019-09-30	54.75%
2019-06-30	56.56%
2019-03-31	55.73%
2018-12-31	55.69%
2018-09-30	55.21%
2018-06-30	55.82%
2018-03-31	56.13%
2017-12-31	54.01%
2017-09-30	45.36%
2017-06-30	57.06%
2017-03-31	54.27%
2016-12-31	52.49%
2016-09-30	54.44%
2016-06-30	56.65%
2016-03-31	55.89%
2015-12-31	52.69%
2015-09-30	57.38%
2015-06-30	59.98%
2015-03-31	61.22%
2014-12-31	50.69%
2014-09-30	54.63%
2014-06-30	57.10%
2014-03-31	61.20%
2013-12-31	65.12%
2013-09-30	66.08%
2013-06-30	66.07%
2013-03-31	54.59%
2012-12-31	65.24%
2012-09-30	53.57%
2012-06-30	49.23%
2012-03-31	57.20%
2011-12-31	0.00%
2011-09-30	70.91%
2011-06-30	74.28%
2011-03-31	70.03%
2010-12-31	73.66%
2010-09-30	74.70%
2010-06-30	76.64%
2010-03-31	74.74%
2009-12-31	74.58%
2009-09-30	76.76%
2009-06-30	68.62%
2009-03-31	64.92%
2008-12-31	73.87%
2008-09-30	72.08%
2008-06-30	84.10%
2008-03-31	60.52%
2007-12-31	62.90%
2007-09-30	73.61%
2007-06-30	71.33%
2007-03-31	75.62%
2006-12-31	79.27%
2006-09-30	68.06%
2006-06-30	72.63%
2006-03-31	69.23%
2005-12-31	72.64%
2005-09-30	68.85%
2005-06-30	77.04%
2005-03-31	65.83%
2004-12-31	54.48%
2004-09-30	45.75%
2004-06-30	59.69%
2004-03-31	58.83%
2003-12-31	40.78%
2003-09-30	47.82%
2003-06-30	58.49%
2003-03-31	50.77%
2002-12-31	52.80%
2002-09-30	60.78%

DATE

GROSS MARGIN

2026-06-30

53.08%

2026-03-31

50.70%

2025-12-31

47.21%

2025-09-30

53.24%

2025-06-30

49.98%

2025-03-31

53.65%

2024-12-31

23.18%

2024-09-30

50.03%

2024-06-30

46.17%

2024-03-31

50.13%

2023-12-31

43.41%

2023-09-30

25.89%

2023-06-30

50.17%

2023-03-31

50.51%

2022-12-31

51.44%

2022-09-30

56.90%

2022-06-30

58.46%

2022-03-31

60.10%

2021-12-31

56.01%

2021-09-30

57.64%

2021-06-30

61.96%

2021-03-31

58.17%

2020-12-31

51.70%

2020-09-30

57.87%

2020-06-30

57.85%

2020-03-31

57.97%

2019-12-31

51.25%

2019-09-30

54.75%

2019-06-30

56.56%

2019-03-31

55.73%

2018-12-31

55.69%

2018-09-30

55.21%

2018-06-30

55.82%

2018-03-31

56.13%

2017-12-31

54.01%

2017-09-30

45.36%

2017-06-30

57.06%

2017-03-31

54.27%

2016-12-31

52.49%

2016-09-30

54.44%

2016-06-30

56.65%

2016-03-31

55.89%

2015-12-31

52.69%

2015-09-30

57.38%

2015-06-30

59.98%

2015-03-31

61.22%

2014-12-31

50.69%

2014-09-30

54.63%

2014-06-30

57.10%

2014-03-31

61.20%

2013-12-31

65.12%

2013-09-30

66.08%

2013-06-30

66.07%

2013-03-31

54.59%

2012-12-31

65.24%

2012-09-30

53.57%

2012-06-30

49.23%

2012-03-31

57.20%

2011-12-31

0.00%

2011-09-30

70.91%

2011-06-30

74.28%

2011-03-31

70.03%

2010-12-31

73.66%

2010-09-30

74.70%

2010-06-30

76.64%

2010-03-31

74.74%

2009-12-31

74.58%

2009-09-30

76.76%

2009-06-30

68.62%

2009-03-31

64.92%

2008-12-31

73.87%

2008-09-30

72.08%

2008-06-30

84.10%

2008-03-31

60.52%

2007-12-31

62.90%

2007-09-30

73.61%

2007-06-30

71.33%

2007-03-31

75.62%

2006-12-31

79.27%

2006-09-30

68.06%

2006-06-30

72.63%

2006-03-31

69.23%

2005-12-31

72.64%

2005-09-30

68.85%

2005-06-30

77.04%

2005-03-31

65.83%

2004-12-31

54.48%

2004-09-30

45.75%

2004-06-30

59.69%

2004-03-31

58.83%

2003-12-31

40.78%

2003-09-30

47.82%

2003-06-30

58.49%

2003-03-31

50.77%

2002-12-31

52.80%

2002-09-30

60.78%

Gross Margin: 51.05%

RGEN Gross Margin

RGEN Average Gross Margin Chart

RGEN Current vs Average Gross Margin Chart

RGEN Gross Margin Metrics

RGEN Competitors' Gross Margin

Gross Margin Analysis

Gross Margin Formula & Definition

Gross Margin FAQ

RGEN Gross Margin History

Related Metrics